Reentry accounts for Ϸ85% of serious tachyarrhythmias complicating ischemic heart disease. Current antiarrhythmic therapies attempt to prevent or treat these arrhythmias by creating bidirectional conduction block, prolonging refractoriness, or both in combination. Implantable defibrillators have had great success in terminating sustained ventricular tachyarrhythmias. However, these therapies possess drawbacks ranging from incomplete arrhythmia suppression to overt toxicity, including proarrhythmia, and the psychological consequence of painful and sometimes inappropriate defibrillation.
A key contributor to many reentrant arrhythmias is slow conduction within part of the reentrant circuit such as a myocardial infarct epicardial border zone. We tested the hypothesis that preserving or speeding conduction through the depolarized surviving myocytes within the border zone would be antiarrhythmic. We focally introduced an adenovirus expressing a skeletal muscle sodium channel (SkM1) that mathematical modeling indicated would operate more efficiently at depolarized membrane potentials than the native cardiac sodium channel (SCN5A). SkM1 preserved conduction in the infarct border zone by increasing the maximum upstroke velocity of action potentials, reflected in situ by narrowing of wide or fragmented electrograms. Electrophysiological testing demonstrated that SkM1 administration significantly decreased the incidence of inducible ventricular tachyarrhythmias. This proof-of-concept study provides evidence that preserving or increasing conduction velocity in the infarct border zone by focal delivery of a gene-based therapy such as overexpression of SkM1 is antiarrhythmic. Unlike traditional drugs, gene therapy interventions are not limited to targeting the native channels expressed by cardiomyocytes but allow delivery of foreign channels with more favorable biophysical properties. See p 19.
Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages
Obesity is associated with an increased risk of cardiovascular morbidity and mortality. The recently discovered endocannabinoid system contributes to the physiological regulation of energy balance and food intake. In several clinical trials, modification of this system by blockade of the cannabinoid 1 (CB1) receptor, one of the receptors in endocannabinoid system, is reported to reduce body weight and to improve multiple cardiometabolic risk factors. Furthermore, a recent clinical study using coronary intravascular ultrasound showed that a CB1 receptor antagonist may favorably influence the progression of atherosclerosis. In this study, we investigated the relationship between the endocannabinoid system and atherogenesis. Results indicated the presence and activation of the endocannabinoid system in patients with coronary artery disease and human atherosclerosis. We demonstrated an increased expression of CB1 receptor in coronary atheromata, particularly in lesional macrophages. Our data further indicate that the CB1 receptor antagonist exhibited antiinflammatory effects on human macrophages. They suggest that CB1 receptor blockade modulates the inflammatory state in atheromata through its antiinflammatory effects on macro-phages. Our study highlights the potential role of the CB1 receptor in atherogenesis and suggests that studies are needed to test the effect of CB1 receptor blockade in vascular disease. See p 28.
Multimarker Approach to Evaluate Correlates of Vascular Stiffness: The Framingham Heart Study
Arterial stiffness increases with age and contributes significantly to cardiovascular morbidity and mortality in the elderly. A better understanding of the pathophysiology of vascular ageing and the biochemical pathways involved might help in the development of appropriate therapeutic strategies. In 2000 Framingham Offspring Study participants, we related 7 biomarkers (C-reactive protein, aldosterone-to-renin ratio, N-terminal proatrial natriuretic peptide and B-type natriuretic peptide, plasminogen activator inhibitor-1, fibrinogen, and homocysteine), representing inflammation, neurohormonal activation, and hemostasis, to a panel of tonometric measures, which reflect the different components of arterial stiffness (ie, central pulse pressure [marker of pulsatile arterial load], mean arterial pressure [marker of steady arterial load], and carotid-femoral pulse-wave velocity [measure of aortic stiffness]). In addition, we analyzed the 2 main components of central pulse pressure: the forward pressure wave amplitude and augmented pressure. We first related the multibiomarker panel as a whole to each vascular function measure and then applied a backward elimination procedure to identify a parsimonious set of markers that displayed the strongest associations with each arterial stiffness measure. We identified the aldosterone-to-renin ratio as a key correlate of pan-arterial stiffness; it was associated with all 5 tonometric measures (PՅ0.002). In addition, plasminogen activator inhibitor-1 displayed an association with central vascular stiffness indices, and CRP showed an association with wave reflection. These observations support the notion that distinct biological pathways may selectively influence the different components of vascular stiffness. See p 37.
Body Mass Index and Vigorous Physical Activity and the Risk of Heart Failure Among Men
In a prospective cohort of 21 094 men (mean age, 53 years) without known coronary heart disease at baseline in the Physicians' Health Study, we examined the individual and combined effects of body mass index (BMI; calculated as weight in kilograms divided by height in meters squared, an anthropometric surrogate of surplus body fat) and vigorous physical activity (defined as exercise to the point of breaking a sweat) on the incidence of heart failure (HF) from 1982 to 2007. During a mean follow-up of 20.5 years, 1109 participants developed new-onset HF. After adjustment for established risk factors for HF, every 1-kg/m 2 increase in BMI was associated with an 11% increase in the risk of HF. Compared with lean participants (BMI Ͻ25 kg/m 2 ), overweight or preobese participants (BMI, 25 to 29.9 kg/m 2 ) had a 49% and obese participants (BMI Ն30 kg/m 2 ) had a 180% increase in HF risk. Vigorous physical activity (at least 1 to 3 times a month) conferred an 18% decrease in HF risk. Lean active men had the lowest and obese inactive men had the highest (290% greater) risk of HF. Our findings support the existence of causal links between excess body weight and HF and sedentary lifestyle and HF. Therefore, given the high prevalence of these 2 modifiable risk factors of HF in the general population, together with the substantial morbidity, mortality, and financial costs imposed by HF, public health measures to curtail excess weight, to 1
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Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics: Principal Results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study
There has been much interest recently in the impact of cardiovascular drugs on central aortic pressures because this impact may influence clinical outcomes. The Conduit Artery Function Evaluation-Lipid-Lowering Arm was a randomized placebo-controlled trial that prospectively examined the impact of atorvastatin (10 mg once daily) on central aortic pressures in hypertensive patients. Atorvastatin did not influence central aortic pressures or hemodynamics in these patients. Thus, the favorable effects of statins on cardiovascular outcomes in hypertensive patients are via mechanisms that are independent of important effects on large-artery function and central pressures. For this reason, the benefits of statins in hypertensive patients are unlikely to be replicated by blood pressure lowering alone. See p 53.
Tissue Doppler Imaging in the Estimation of Intracardiac Filling Pressure in Decompensated Patients With Advanced Systolic Heart Failure
The ratio of early transmitral velocity to tissue Doppler mitral annular early diastolic velocity (E/Ea) has been correlated with pulmonary capillary wedge pressure in a wide variety of cardiac conditions. However, the reliability of the mitral E/Ea ratio for predicting pulmonary capillary wedge pressure in patients admitted for advanced decompensated heart failure is unknown. A total of 106 prospective consecutive patients with advanced decompensated heart failure (ejection fraction Յ30%, New Your Heart Association class III to IV symptoms) underwent simultaneous echocardiographic and hemodynamic evaluation on admission and after 48 hours of intensive medical therapy. We found the predictive value of baseline mitral E/Ea ratio in estimating pulmonary capillary wedge pressure to be less robust than previously reported, which appears to be related to larger left ventricular dimensions, more impaired cardiac output, and the presence of cardiac resynchronization therapy. In addition, no reliable direct correlation between baseline or changes in mitral E/Ea ratio and pulmonary capillary wedge pressure was found. Taken together, our observations provide an important refinement in the clinical interpretation of the mitral E/Ea ratio as it applies to patient populations in which important confounders such as alterations in myocardial structure, severity of systolic dysfunction, or the presence of synchronized pacing may pose challenges to the accurate prediction of left ventricular filling pressures. See p 62.
Randomized Study of the Crush Technique Versus Provisional Side-Branch Stenting in True Coronary Bifurcations: The CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study
The optimal strategy in the percutaneous treatment of true coronary bifurcation lesions has not been fully clarified. In this 350-patient randomized multicenter trial, we compared the "crush" technique of electively stenting both branches versus stenting only the main branch, with provisional side-branch stenting if needed, with sirolimus-eluting stents. Regardless of the technique used, sirolimus-eluting stent implantation in true bifurcation lesions results in good clinical and angiographic results with acceptable midterm safety. The rates of angiographic restenosis, stent thrombosis, and major adverse cardiovascular events at 6 months were similar in both groups. Thus, in most bifurcations with a significant stenosis in both branches, a provisional strategy of stenting the main branch only is effective, with the need to implant a second stent on the side branch occurring in approximately one third of cases. However, if 2 stents are required and are implanted with the crush technique, there appears to be no increased risk of adverse events at 6 months. See p 71.
Critical Role of Transcription Factor Cyclic AMP Response Element Modulator in ␤ 1 -Adrenoceptor-Mediated Cardiac Dysfunction
Heart failure, the common end stage of various cardiac diseases, is defined as the inability of the heart to cover the body's blood supply and is associated with a poor prognosis. Supported by clinical studies and studies on various animal models, chronic stimulation of the ␤ 1 -adrenoceptor (␤ 1 AR) by elevated plasma catecholamines is regarded as a central pathogenetic factor of human heart failure, leading to the progression of the disease. Transcription factors of the cyclic AMP response element binding protein/cyclic AMP response element modulator (CREM) family mediate a cyclic AMP-dependent control of gene expression and may therefore contribute to ␤ 1 AR-mediated detrimental cardiac effects. In the present study, we show that the inactivation of CREM protects from cardiomyocyte hypertrophy, fibrosis, and left ventricular dysfunction in mice with heart-directed expression of the ␤ 1 AR, along with the altered expression of various myocardial proteins including the cardiac ryanodine receptor, tropomyosin 1␣, and cardiac ␣-actin. These findings support the notion that the regulation of genes by CREM represents an important mechanism of ␤ 1 AR-induced cardiac damage and suggest the inhibition of CREM as a promising therapeutic option for treating heart failure. See p 79.
Myocardial Adeno-Associated Virus Serotype 6 -␤ARKct Gene Therapy Improves Cardiac Function and Normalizes the Neurohormonal Axis in Chronic Heart Failure
A number of previous reports have suggested that cardiac G protein-coupled receptor kinase 2 inhibition, via the use of the peptide inhibitor ␤ARKct, could be a potential novel gene therapy for heart failure (HF). However, these studies tested the effects of ␤ARKct expression in transgenic mice or with short-term gene transfer experiments, and thus no clinically relevant conclusions about the long-term efficacy and adverse effects can be drawn. The present study investigated the long-term nature of ␤ARKct gene therapy in HF, providing proof of concept for its sustained therapeutic effects in the context of a relevant experimental model of HF. Taking advantage of adeno-associated virus-mediated gene transfer, which enables efficient and sustained transgene expression, cardiac ␤ARKct gene delivery restored contractile dysfunction and reversed cardiac remodeling of chronically failing hearts. Mechanistically, this appears to be mediated by a normalization of cardiac ␤-adrenergic receptor signaling as well as lowering of gene expression associated with adverse left ventricular remodeling. Moreover, long-term myocardial ␤ARKct expression leads to neurohormonal feedback decreasing the hyperactivity of the sympathetic nervous system and renin-angiotensin-aldosterone axis in HF. Finally, ␤ARKct therapeutic properties were superior even to metoprolol, a clinically established HF therapy in humans, which was able only to prevent but not reverse (as the ␤ARKct did) progressive deterioration of contractile function. Therefore, this study shows that ␤ARKct gene therapy can be of long-term therapeutic value in HF, although testing of ␤ARKct gene therapy in large animals and in patients will ultimately define its place in the HF therapeutic armamentarium. See p 89.
Acute Doxorubicin Cardiotoxicity Is Associated With p53-Induced Inhibition of the Mammalian Target of Rapamycin Pathway
Anthracyclines are widely used and highly successful anticancer chemotherapeutic drugs. Unfortunately, these drugs also cause acute cardiotoxicity, such as arrhythmia and transient depression of left ventricular function, and higher cumulative doses are associated with late-onset refractory cardiomyopathy and heart failure. Because anthracyclines can interfere with many different intracellular processes, it has proven difficult to determine the exact mechanisms that give rise to acute versus chronic cardiotoxicity. This study examined acute cardiotoxicity in mice treated with the anthracycline doxorubicin. Treated mice exhibited a marked decrease in cardiac function acutely that was accompanied by a reduction in cardiac mass. Molecular analyses suggested that doxorubicin treatment increased levels of the tumor suppressor protein p53, which in turn inhibited the activity of mammalian target of rapamycin (mTOR). Inhibition of mTOR activity is predicted to decrease the translation of new proteins. In support of this mechanism, genetically modified mice expressing either dominant-interfering p53 or constitutively active mTOR exhibited normal cardiac function and mass after doxorubicin treatment. Interestingly, rescue of cardiac function and structure during acute cardiotoxicity was not associated with reduction of doxorubicin-induced cardiomyocyte apoptosis. These data suggest that coadministration of mTOR activators might decrease acute doxorubicin cardiotoxicity, thereby permitting a higher dose of drug per treatment. If so, administration of fewer doses of anthracycline at higher levels might be a more effective anticancer strategy. This approach may also allow lower cumulative doses, which would reduce the incidence of late-onset refractory cardiomyopathy. See p 99.
Get With the Guidelines-Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack
Stroke is the third-leading cause of death and a leading cause of long-term disability. Despite widely available evidence supporting clinical interventions that improve health outcomes for patients hospitalized for acute ischemic stroke or transient ischemic attack, many patients do not receive these recommended interventions. Get With the Guidelines-Stroke is a program of the American Heart Association/American Stroke Association (AHA/ASA) to improve the quality of care of patients with stroke and transient ischemic attack. In this study, Get With the Guidelines-Stroke participation was associated with sustained and substantial improvements in a wide variety of acute stroke care and secondary prevention performance measures over Ͼ4 years across a spectrum of participating hospitals. This is the largest report to date of improvements in acute stroke care and confirms the sustainability and generalizability of the improvements observed in the pilot phase of the program. In addition, the analyses suggest that the benefit of the program was independent of secular trends in acute stroke care. The study shows the impact of the program on hospitalized stroke patients and has broad implications for the ability to improve stroke care across the country. If patients continue to adhere to secondary prevention regimens after discharge, clinical trial data suggest a substantial reduction in stroke recurrence applicable to many tens of thousands of patients each year. Increased support for stroke quality initiatives would likely yield substantial improvements in quality of care and clinical outcomes for stroke and transient ischemic attack and translate into substantial healthcare savings. See p 107.
Platelet P2Y 12 Receptor Influences the Vessel Wall Response to Arterial Injury and Thrombosis
The platelet P2Y 12 receptor plays a major role in platelet activation and the ensuing thrombotic and inflammatory responses. Platelets are believed to play a role in the neointima formation that results from arterial injury such as after percutaneous coronary intervention or as a consequence of vessel wall inflammation, as occurs with atherosclerosis. We have determined the role of the P2Y 12 receptor in the vessel wall response after arterial injury in mouse models using P2Y 12 receptor knockout mice as well as the P2Y 12 receptor antagonist clopidogrel to investigate the role of the receptor. We have shown that the P2Y 12 receptor plays a substantial role in promoting neointima formation and, through bone marrow transplantation experiments, have demonstrated that it is specifically the receptors on platelets that mediate this response. This suggests that more effectively targeting the platelet P2Y 12 receptor before percutaneous coronary intervention might prove effective in reducing restenosis and could also have a beneficial inhibitory effect on atherogenesis during long-term administration of P2Y 12 antagonists. See p 116.
Disparity in Outcomes of Surgical Revascularization for Limb Salvage: Race and Gender Are Synergistic Determinants of Vein Graft Failure and Limb Loss
Racial and ethnic disparities in the prevalence of peripheral artery disease and its most severe complication, limb loss, have been described. However, the variability in outcomes for revascularization therapies such as surgery or angioplasty is poorly characterized. Surgical bypass using an autogenous vein is an effective and durable treatment for many patients with the most advanced form of peripheral arterial disease, critical limb ischemia. We examined the relationship between patient demographics (race and gender) and the outcomes of vein bypass procedures for critical limb ischemia using a large (nϭ1404) multicenter randomized trial database from Ͼ80 North American institutions. Aggressive bypass graft surveillance with duplex ultrasonography was incorporated into the study protocol to reliably identify significant vein graft lesions. Propensity score methods were applied to control for covariates while focusing on the interaction between race and gender. Our findings demonstrate that black patients, particularly women, are at increased risk for vein graft failure and limb loss after surgical revascularization for critical limb ischemia. The data suggest the possibility of an altered response to vein bypass surgery in this subgroup. Aggressive medical therapy and close surveillance are mandated in these higher-risk cohorts to improve the chances of long-term success. Further studies are indicated to determine the mechanisms underlying these observations. See p 123.
Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation
Although cholesterol lowering by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins is clearly linked to decreased cardiovascular disease, several recent statin trials suggest additional benefits beyond cholesterol lowering, possibly by mechanisms
